Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 5, 1999, Pages 306-315

  Lee, Jung Lim ^a   Gooley, Ted ^a   Bensinger, William ^a   Schiffman, Kathy ^a   McDonald, George B ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Alkylating agents; Bone marrow transplantation; Breast cancer; Lymphoma; Multiorgan failure; Peripheral blood stem cells; Renal failure; Toxic reactions; Veno occlusive disease

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER DISEASE; LIVER VEIN OBSTRUCTION; MALE; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; RADIOTHERAPY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; LIVER DISEASES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; RADIOTHERAPY; RISK FACTORS; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0032620465     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(99)70006-6     Document Type: Article

References (61)

1. McDonald GB, Hinds MS, Fisher LB, Schock HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255, 1993.
2. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85:3005, 1995.
3. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127:549, 1987.
4. Shulman HM, Fisher LB, Schock HG, Henne KW, McDonald GB: Veno-occlusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms. Hepatology 19:1171, 1994.
5. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Phannacol 25:55, 1989.
6. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochov LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987.
7. Grochow LB: Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20 (Suppl 4):18, 1993.
8. DeLeve LD: Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 268:1261, 1994.
9. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N: Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic veno-occlusive disease. Hepatology 23:589, 1996.
10. DeLeve LD, Wang XD, Huybrechts MM: Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24:830, 1996.
11. Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connagham DG, Hillyer CD, Hughes LL, Miller RL, Moore MR, Winton EF, Wingard JR: Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 14:1156, 1996.
12. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E III, Antman K: A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239, 1990.
13. Antmann K, Ayasb L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102, 1992.
14. van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schornagel JH, Richel DJ, Rutgers EJT, Slaper-Cortenbach ICM, van der Schoot CE, Rodenbuis S: High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 71:857, 1995.
15. Tomas JF, Perez-Carrion R, Escudero A, Lopez-Lorenzo JL, Lopez-Pascual J, Fernandez-Ranada JM: Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 19:331, 1997.
16. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach ICM, Schornagel JH: Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer of germ cell cancer. J Clin Oncol 14:1473, 1996.
17. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mebra R, van Besien K, Delasalle KB, Reading C, Deisseroth AB, Champlin RE: Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324, 1993.
18. Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R: A phase I-II study of high-dose thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449, 1994.
19. Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Champlin RE: Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 68:183, 1994.
20. Avet Loiseau H, Hartmann O, Valteau D, McDowell H, Brugieres L, Vassal G, Kalifa C, Patte C, Lemerle J: High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 8:465, 1991.
21. Srivastava A, Bradstock KF, Szer J, de Bortoli L, Gottlieb DJ: Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 12:323, 1993.
22. Phillips GL, Shepherd JD, Barnett MJ, Lansdorp PM, Klingemann H-G, Spinelli JJ, Nevill TJ, Chan K-W, Reece DE: Busulfan, cyclophosphamide, melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 9:1880, 1991.
23. Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T: Phase I study of high dose busulfan, melphalan, and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 14:813, 1994.
24. Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgmnery P, Maziarz R, Klarnet JP, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner CD: Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 17:943, 1996.
25. Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, Shulman HM, McDonald GB, Thomas ED: Veno-occlusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 43:870, 1987.
26. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP: Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 8:1699, 1990.
27. Strasser SI, McDonald GB: Hepatobiliary complications of hematopoietic cell transplantation. In: Schiff ER, Sorrell MF, Maddrey WC (eds) Schiff's Diseases of the Live. Philadelphia: Lippincott-Raven.
28. Clelland BD, Pokorny CS: Cyclophosphamide related hepatotoxicity. Aust N Z J Med 23:408, 1993.
29. Modzelewski JR, Daeschner C, Joshi VV, Mullick FG, Ishak KG: Veno-occlusive disease of the liver induced by low dose cyclophosphamide. Mod Pathol 7:967, 1994.
30. Honjo I, Suou T, Hirayama C: Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res Commun Chem Pathol Pharmacol 61:149, 1988.
31. Schuler U, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller K-P, Ehninger G: Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 14:759, 1994.
32. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055, 1997.
33. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31, 1995.
34. Hassan M, Ehrsson H, Ljungman P: Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 22:395, 1996.
35. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484, 1996.
36. Brodsky R, Topolsky D, Crilley P, Bulova S, Brodsky I: Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 13:221, 1990.
37. DeLeve LD, Wang X: Identification of two distinct mechanisms of busulfan toxicity in isolated murine hepatocytes (Abstract). Hepatology 24:464A, 1996.
38. Samuels BL, Bitran JD: High-dose intravenous melphalan: a review. J Clin Oncol 13:1786, 1995.
39. Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL: Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 15:660, 1997.
40. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12:37, 1994.
41. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J: Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 18:1049, 1996.
42. Viens P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, Plagne R, Dufour P, Bergerat JP, Guastalla JP, Rozenbaum A, Carcassonne Y: High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 5:227, 1990.
43. Harousseau JL, Milpied N, Laporte JP, Callombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827, 1992.
44. Zulian GB, Selby P, Milan S, Nandi A, Gore M, Forgeson G, Perren TJ, McElwain TJ: High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer 59:631, 1989.
45. Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J, White W: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17:157, 1996.
46. Gouyette A, Hartmann O, Pico J-L: Phamacokinetics of high-dose melphalan in children and and adults. Cancer Chemother Pharmacol 16:184, 1986.
47. Tranchand B, Ploin YD, Minuit MP, Sapet C, Biron P, Philip T, Ardiet C: High-dose melphalan dosage adjustment: possibility of using a test-dose. Cancer Chemother Pharmacol 23:95, 1989.
48. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12:194, 1994.
49. Ng SF, Waxman DJ: Biotransformation of N,N′N″-triethylenethiophosphoramide: oxidative desulfuration to yield N,N′,N″-triethylenethiophosphoramide associated with suicide inactivation of phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res 50:464, 1990.
50. Ng SF, Waxman DJ: N,N′,N″-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. Cancer Res 51:2340, 1991.
51. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M: Dosing of ThioTEPA for myeloablative therapy. Cancer Chemother Pharmacol 37:155, 1995.
52. O'Dwyer PJ, LaCreta F, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, DeVito J, Poplack D, DeLap RJ, Comis RL: Phase 1/pharmacokinetic reevaluation of ThioTEPA. Cancer Res 51:3171, 1991.
53. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singber LJ, Ettinger LJ, Gillespie A, Sam J, Poplack DG: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736, 1989.
54. O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR, Ozols RF: Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 10:1352, 1992.
55. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL: High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689, 1987.
56. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB: Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11:1729, 1993.
57. Farrand AL, Nash RA, Zager RA, Gmur D, McDonald GB: Pathogenesis of veno-occlusive disease of the liver: role of cytokines, NO, endothelin-1, and fibrosis (Abstract). Gastroenterology 110:A1189, 1996.
58. Rubenfeld GD, Crawford SW: Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 125:625, 1996.
59. Haire WD, Ruby EI, Gordon BG, Patil KD, Stephens LC, Kotulak GD, Reed EC, Vose JM, Bierman PJ, Kessinger A, Armitage JO: Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA 274:1289, 1995.
60. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shuhman HM, Gamelin LM, Stewart P, Thomas ED: Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 13:210, 1989.
61. Fink J, Cooper M, Burkhart K, McDonald GB, Zager RA: Marked enzymuria following bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome." J Am Soc Nephrol 6:1655, 1995.